|
1
|
Willett WC: Diet and cancer: One view at
the start of the millennium. Cancer Epidemiol Biomarkers Prev.
10:3–8. 2001.PubMed/NCBI
|
|
2
|
Arnold M, Pandeya N, Byrnes G, Renehan
PAG, Stevens GA, Ezzati PM, Ferlay J, Miranda JJ, Romieu I, Dikshit
R, et al: Global burden of cancer attributable to high body-mass
index in 2012: A population-based study. Lancet Oncol. 16:36–46.
2015. View Article : Google Scholar :
|
|
3
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar
|
|
4
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
5
|
Labianca R, Nordlinger B, Beretta GD,
Mosconi S, Mandalà M and Cervantes A: Early colon cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 24(Suppl 6): vi64–vi72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Voigt AP, Eidenschink Brodersen L, Pardo
L, Meshinchi S and Loken MR: Consistent quantitative gene product
expression: #1. Automated identification of regenerating bone
marrow cell populations using support vector machines. Cytometry A.
89:978–986. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
den Uil SH, Coupe VM, Linnekamp JF, van
den Broek E, Goos JA, Delis-van Diemen PM, Belt EJ, van Grieken NC,
Scott PM, et al: KCNQ1 expression is a strong prognostic biomarker
for disease recurrence in stage II and III colon cancer. AACR 107t.
Annual Meeting. 76:31252016.
|
|
8
|
Woischke C, Blaj C, Schmidt EM, Lamprecht
S, Engel J, Hermeking H, Kirchner T and Horst D: CYB5R1 links
epithelial-mesenchymal transition and poor prognosis in colorectal
cancer. Oncotarget. 7:31350–31360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kandimalla R, Linnekamp JF, van Hooff S,
Castells A, Llor X, Andreu M, Jover R, Goel A and Medema JP:
Methylation of WNT target genes AXIN2 and DKK1 as robust biomarkers
for recurrence prediction in stage II colon cancer. Oncogenesis.
6:e3082017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Toiyama T, Hur K, Tanaka K, Inoue Y,
Kusunoki M, Boland CR and Goel A: Serum miR-200c is a novel
prognostic and metastasis-predictive biomarker in patients with
colorectal cancer. Ann Surg. 259:735–743. 2014. View Article : Google Scholar :
|
|
11
|
Marisa L, de Reyniès A, Duval A, Selves J,
Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D,
Ayadi M, et al: Gene expression classification of colon cancer into
molecular subtypes: Characterization, validation, and prognostic
value. PLoS Med. 10:e10014532013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carvalho BS and Irizarry RA: A framework
for oligonucleotide microarray preprocessing. Bioinformatics.
26:2363–2367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang P, Wang Y, Hang B, Zou X and Mao JH:
A novel gene expression-based prognostic scoring system to predict
survival in gastric cancer. Oncotarget. 7:55343–55351.
2016.PubMed/NCBI
|
|
14
|
Smoot ME, Ono K, Ruscheinski J, Wang PL
and Ideker T: Cytoscape 2.8: New features for data integration and
network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar :
|
|
15
|
Yu G, Wang LG, Han Y and He QY:
ClusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reimand J, Tooming L, Peterson H, Adler P
and Vilo J: GraphWeb: Mining heterogeneous biological networks for
gene modules with functional significance. Nucleic Acids Res.
36(Web Server Issue): W452–459. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Van Gestel T, Suykens JA, Lanckriet G,
Lambrechts A, De Moor B and Vandewalle J: Bayesian framework for
least-squares support vector machine classifiers, gaussian
processes, and kernel Fisher discriminant analysis. Neural Comput.
14:1115–1147. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eisen MB, Spellman PT, Brown PO and
Botstein D: Cluster analysis and display of genome-wide expression
patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng
Z, Zhu G, Qi J, Ma H, Nian H and Wang Y: RNA-seq analyses of
multiple meristems of soybean: Novel and alternative transcripts,
evolutionary and functional implications. BMC Plant Biol.
14:1692014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang W, Du WW, Li X, Yee AJ and Yang BB:
Foxo3 activity promoted by non-coding effects of circular RNA and
Foxo3 pseudogene in the inhibition of tumor growth and
angiogenesis. Oncogene. 35:3919–3931. 2016. View Article : Google Scholar
|
|
22
|
Wanga Y, Kanga XL, Zenga FC, Xua CJ, Zhoua
JQ and Luo DN: Correlations of Foxo3 and Foxo4 expressions with
clinico-pathological features and prognosis of bladder cancer.
Pathol Res Pract. 213:766–772. 2017. View Article : Google Scholar
|
|
23
|
Savkovic SD: Decreased FOXO3 within
advanced human colon cancer: Implications of tumour suppressor
function. Br J Cancer. 109:297–298. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bullock MD, Bruce A, Sreekumar R, Curtis
N, Cheung T, Reading I, Primrose JN, Ottensmeier C, Packham GK,
Thomas G and Mirnezami AH: FOXO3 expression during colorectal
cancer progression: Biomarker potential reflects a tumour
suppressor role. Br J Cancer. 109:387–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Davudian S, Mansoori B, Shajari N,
Mohammadi A and Baradaran B: ACH1, the master regulator gene: A
novel candidate target for cancer therapy. Gene. 588:30–37. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee J, Yun J, Yeung K, Bevilacqua E,
Balázsi G and Rosner MR: Abstract A39: BACH1 and RKIP participate
in a bistable network that affects progression to metastasis in
breast Cancer. Cancer Res. 73:2013.
|
|
27
|
Davudian S, Shajari N, Kazemi T, Mansoori
B, Salehi S, Mohammadi A, Shanehbandi D, Shahgoli VK, Asadi M and
Baradaran B: BACH1 silencing by siRNA inhibits migration of HT-29
colon cancer cells through reduction of metastasis-related genes.
Biomed Pharmacother. 84:191–198. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chai EZ, Shanmugam MK, Arfuso F,
Dharmarajan A, Wang C, Kumar AP, Samy RP, Lim LH, Wang L, Goh BC,
et al: Targeting transcription factor STAT3 for cancer prevention
and therapy. Pharmacol Ther. 162:86–97. 2016. View Article : Google Scholar
|
|
29
|
Bourgeais J, Gouilleux-Gruart V and
Gouilleux F: Oxidative metabolism in cancer: A STAT affair.
JAKSTAT. 2:e257642013.
|
|
30
|
Xiong H, Su WY, Liang QC, Zhang ZG, Chen
HM, Du W, Chen YX and Fang JY: Inhibition of STAT5 induces G1 cell
cycle arrest and reduces tumor cell invasion in human colorectal
cancer cells. Lab Invest. 89:717–725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Klupp F, Diers J, Kahlert C, Neumann L,
Halama N, Franz C, Schmidt T, Lasitschka F, Warth A, Weitz J, et
al: Expressional STAT3/STAT5 ratio is an independent prognostic
marker in colon carcinoma. Ann Surg Oncol. 22(Suppl 3):
S1548–S1555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheon DJ, Beach J, Walts A, Karlan B and
Orsulic S: Abstract A39: COL11A1 is a regulator of tumor
microenvironment and a biomarker of metastatic progression. Cancer
Res. 75:2015. View Article : Google Scholar
|
|
33
|
Wu YH, Chang TH, Huang YF, Huang HD and
Chou CY: COL11A1 promotes tumor progression and predicts poor
clinical outcome in ovarian cancer. Oncogene. 33:3432–3440. 2014.
View Article : Google Scholar
|
|
34
|
Fischer H, Stenling R, Rubio C and
Lindblom A: Colorectal carcinogenesis is associated with stromal
expression of COL11A1 and COL5A2. Carcinogenesis. 22:875–878. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Benard A, Goossens-Beumer IJ, van Hoesel
AQ, Horati H, Putter H, Zeestraten EC, van de Velde CJ and Kuppen
PJ: Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and
histone modification H3K27me3 in colorectal cancer. PLoS One.
9:e1082652014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Katoh M: Frequent up-regulation of WNT2 in
primary gastric cancer and colorectal cancer. Int J Oncol.
19:1003–1007. 2001.PubMed/NCBI
|
|
37
|
Katoh M: WNT2 and human gastrointestinal
cancer (review). Int J Mol Med. 12:811–816. 2003.PubMed/NCBI
|
|
38
|
Jung YS, Jun S, Lee SH, Sharma A and Park
JI: Wnt2 complements Wnt/β-catenin signaling in colorectal cancer.
Oncotarget. 6:37257–37268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Klaus A and Birchmeier W: Wnt signalling
and its impact on development and cancer. Nat Rev Cancer.
8:387–398. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
West NJ, Courtney ED, Poullis AP and
Leicester RJ: Apoptosis in the colonic crypt, colorectal adenomata,
and manipulation by chemoprevention. Cancer Epidemiol Biomarkers
Prev. 18:1680–1687. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chikazawa N, Tanaka H, Tasaka T, Nakamura
M, Tanaka M, Onishi H and Katano M: Inhibition of Wnt signaling
pathway decreases chemotherapy-resistant side-population colon
cancer cells. Anticancer Res. 30:2041–2048. 2010.PubMed/NCBI
|
|
42
|
Komatsu N, Takata M, Otsuki N, Toyama T,
Ohka R, Takehara K and Saijoh K: Expression and localization of
tissue kallikrein mRNAs in human epidermis and appendages. J Invest
Dermatol. 121:542–549. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mo L, Zhang J, Shi J, Xuan Q, Yang X, Qin
M, Lee C, Klocker H, Li QQ and Mo Z: Human kallikrein 7 induces
epithelial-mesen-chymal transition-like changes in prostate
carcinoma cells: A role in prostate cancer invasion and
progression. Anticancer Res. 30:3413–3420. 2010.PubMed/NCBI
|
|
44
|
Bayani J and Diamandis EP: The physiology
and pathobiology of human kallikrein-related peptidase 6 (KLK6).
Clin Chem Lab Med. 50:211–233. 2012. View Article : Google Scholar
|
|
45
|
Ignatenko NA, Zhang H, Watts GS, Skovan
BA, Stringer DE and Gerner EW: The chemopreventive agent alpha-difl
uoromethylornithine blocks ki-ras-dependent tumor formation and
specifi c gene expression in caco-2 cells. Mol Carcinog.
39:221–233. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
Seiz L, Dorn J, Kotzsch M, Walch A,
Grebenchtchikov I, Gkazepis A, Schmalfeldt B, Kiechle M, Bayani J,
Diamandis EP, et al: Stromal cell-associated expression of
kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of
ovarian cancer patients. Biol Chem. 393:391–401. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rückert F, Hennig M, Petraki CD, Wehrum D,
Distler M, Denz A, Schröder M, Dawelbait G, Kalthoff H, Saeger HD,
et al: Co-expression of KLK6 and KLK10 as prognostic factors for
survival in pancreatic ductal adenocarcinoma. Br J Cancer.
99:1484–1492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Petraki C, Dubinski W, Scorilas A, Saleh
C, Pasic MD, Komborozos V, Khalil B, Gabril MY, Streutker C,
Diamandis EP and Yousef GM: Evaluation and prognostic significance
of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal
cancer. Pathol Res Pract. 208:104–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
